Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Mann, Johannes; Schmieder, Roland; McQueen, Matthew; Dyal, Leanne; Schumacher, Helmut; Pogue, Janice; Wang, Xingyu; Maggioni, Aldo; Budaj, Andrzej; Chaithiraphan, Suphachai; Dickstein, Kenneth; Keltai, Matyas; Metsarinne, Kaj; Oto, Ali; Parkhomenko, Alexander; Piegas, Leopoldo; Svendsen, Tage; Teo, Koon; Yusuf, Salim

doi:10.1016/s0140-6736(08)61236-2

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Mann J. F. E., Schmieder R. E., McQueen M., Dyal L., Schumacher H., Pogue J., ...Daha Fazla

LANCET, cilt.372, sa.9638, ss.547-553, 2008 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 372 Sayı: 9638
Basım Tarihi: 2008
Doi Numarası: 10.1016/s0140-6736(08)61236-2
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.547-553
Hacettepe Üniversitesi Adresli: Evet

Özet

Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage.